









Markets
/
Stocks
/
nasdaq-hbio
/

Harvard Bioscience Inc

HBIO

0.469USD

-0.015-3.04%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

20.87MMarket Cap

LossP/E TTM



Harvard Bioscience Inc

0.469

-0.015-3.04%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

101 / 207

Overall Ranking

220 / 4720

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Buy

Current Rating

2.000

Target Price

+313.82%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bioproduction and preclinical testing for pharmaceutical and therapy development. Its products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. The CMT product family is primarily composed of products supporting research related to molecular, cellular, organ and organoid technologies. The Preclinical product family includes products that support the preclinical research and testing phase for drug development, and in particular, testing related to data collection and analysis for safety and regulatory compliance.

Growing

The company is in a growing phase, with the latest annual income totaling USD 94.14M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 30.36.

Fairly Valued

The company’s latest PE is -0.36, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 34.64M shares, decreasing 16.84% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 1.85M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.72.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.83, which is lower than the Healthcare Equipment & Supplies industry's average of 7.32. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 20.45M, representing a year-over-year decrease of 11.46%, while its net profit experienced a year-over-year decrease of 22.04%.

Score

Industry at a Glance

Previous score

6.83

Change



Financials

6.14

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

5.43

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

8.69

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.70

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.16

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Healthcare Equipment & Supplies industry's average of 3.59. Its current P/E ratio is -0.37, which is -7.99% below the recent high of -0.34 and -504.25% above the recent low of -2.25.

Score

Industry at a Glance

Previous score

2.80

Change

1.2

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 101/207

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 7.00, which is lower than the Healthcare Equipment & Supplies industry's average of 7.70. The average price target for Harvard Bioscience Inc is 2.00, with a high of 2.00 and a low of 2.00.

Score

Industry at a Glance

Previous score

7.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts

Buy

Current Rating

2.000

Target Price

+313.82%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Harvard Bioscience Inc

HBIO

Boston Scientific Corp

BSX

Edwards Lifesciences Corp

Intuitive Surgical Inc

ISRG

Veeva Systems Inc

VEEV

Thermo Fisher Scientific Inc

TMO

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 6.38, which is lower than the Healthcare Equipment & Supplies industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 0.56 and the support level at 0.41, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.38

Change

-0.15

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(4)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

0.001

Neutral

RSI(14)

48.622

Neutral

STOCH(KDJ)(9,3,3)

36.839

Neutral

ATR(14)

0.034

Low Volatility

CCI(14)

17.182

Neutral

Williams %R

65.286

Sell

TRIX(12,20)

-0.334

Sell

StochRSI(14)

68.268

Sell

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

0.468

Buy

MA10

0.457

Buy

MA20

0.478

Sell

MA50

0.480

Sell

MA100

0.452

Buy

MA200

0.877

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 7.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.89. The latest institutional shareholding proportion is 78.35%, representing a quarter-over-quarter decrease of 2.62%. The largest institutional shareholder is The Vanguard, holding a total of 1.85M shares, representing 4.16% of shares outstanding, with 15.85% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

AMH Equity, Ltd.

3.60M

-4.52%

Weber Capital Management, LLC

3.20M

+27.15%

Harvey Partners, LLC

2.19M

-18.47%

The Vanguard Group, Inc.

Star Investors

2.14M

-0.89%

Green (James W)

2.03M

+20.74%

272 Capital LLC

1.56M

Granahan Investment Management, LLC

1.53M

-5.52%

Dimensional Fund Advisors, L.P.

1.44M

-13.65%

BlackRock Institutional Trust Company, N.A.

2.54M

-6.09%

Acadian Asset Management LLC

1.08M

+7.84%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 2.96, which is lower than the Healthcare Equipment & Supplies industry's average of 3.87. The company's beta value is 1.54. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.